Physician profile
Meghan Hoffner
NPI 1881902369
$85,682.09
in general payments reported to CMS, 2019-2025
20 companies · $37K in 2025
The $37K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $7,806 · 2022: $16K · 2023: $15K · 2024: $9,788 · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Food and Beverage: $5,523 · Travel and Lodging: $5,337 · Consulting Fee: $1,200 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $49,970.50 |
| Food and Beverage | $5,523.35 |
| Travel and Lodging | $5,337.34 |
| Consulting Fee | $1,200.00 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $48,055.82 | 2021-2025 | |
| Amgen INC. | $18,531.28 | 2021-2025 | Otezla, Otezla, Enbrel |
| Janssen Biotech, INC. | $16,087.61 | 2022-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $1,380.91 | 2021-2024 | Cimzia, Bimzelx |
| Astrazeneca Pharmaceuticals LP | $364.29 | 2022-2023 | Saphnelo |
| Glaxosmithkline, LLC. | $217.37 | 2022-2023 | Benlysta |
| Novartis Pharmaceuticals Corporation | $195.96 | 2022-2023 | |
| Aurinia Pharma U.S., INC. | $144.49 | 2021-2024 | Lupkynis |
| Sanara Medtech INC. | $144.06 | 2025 | Celleraterx |
| Horizon Therapeutics Plc | $137.75 | 2023 | Krystexxa |
| Janssen Scientific Affairs, LLC | $108.45 | 2022 | |
| Scilex Pharmaceuticals INC. | $71.93 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $53.20 | 2022-2023 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.32 | 2023 | Ofev, Cyltezo |
| Pfizer INC. | $30.86 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $27.69 | 2023 | Renflexis, Hadlima |
| Sobi, INC | $24.98 | 2022 | |
| Lilly USA, LLC | $24.75 | 2023 | Taltz |
| Alexion Pharmaceuticals, INC. | $18.29 | 2023 | Strensiq |
| Genentech USA, INC. | $13.08 | 2023 | Actemra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meghan Hoffner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.